A man who said he was ready to die for Allah was shot dead on Saturday after attacking a soldier at Paris's Orly airport, triggering a major security alert that caused travel chaos. Ziyed Ben Belgacem, a 39-year-old French national, grabbed a female soldier and put a gun to her head, seizing her assault rifle, Paris prosecutor Francois Molins told a press conference. In any case people are going to die," the attacker told the troops in Molins's account of the attack.
By Bill Berkrot WASHINGTON (Reuters) - Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday. New guidelines for blood vessel size and proper implantation techniques put in place for the new Absorb stent since the study began, however, should lead to better results, researchers said. "The difference between Absorb and Xience when they're both implanted in properly-sized vessels with good procedural technique is likely to be quite modest and possibly not clinically important," said Dr. Stephen Ellis, director of interventional cardiology at Cleveland Clinic, who presented the data at the American College of Cardiology scientific meeting in Washington.
No comments:
Post a Comment